<DOC>
	<DOCNO>NCT01496703</DOCNO>
	<brief_summary>Mycophenolate mofetil ( MMF ) decrease risk acute rejection associate improved graft survival renal transplant recipient . However , MMF-related side effect often necessitate dose reduction may expose transplant recipient high risk acute rejection graft loss . This study 's aim examine reason MMF dose reduction first year kidney transplantation impact acute rejection , overall death-censored graft loss . Methods : Retrospective electronic file base analysis patient underwent single kidney transplantation center 1996 2007 treat MMF part initial maintenance immunosuppressive protocol ( n=749 ) .</brief_summary>
	<brief_title>Reasons Mycophenolate Mofetil Dose Reduction Impact Graft Outcome Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>All patient receive single renal transplant University Hospitals Leuven April 1996 ( MMF introduce Leuven renal transplant program ) February 2007 treat MMF ( CellceptÂ® , Roche ) part initial maintenance immunosuppressive regimen include retrospective analysis . If patient underwent one kidney transplantation abovementioned 11year period , last consider .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>reason MMF dose reduction</keyword>
</DOC>